BioCentury | Jan 21, 2021
Management Tracks

BIO restructures, downsizes as COVID takes toll on in-person events

BIO has restructured its senior management team. It also downsized in response to COVID-19 policies that have forced it to cancel planned in-person conferences and events. The trade association said it expects to hold only...
BioCentury | Jan 20, 2021
Politics, Policy & Law

Exit interview: Hahn departs after tumultuous tenure, advocating greater independence for FDA

FDA Commissioner Stephen Hahn presided over the most tumultuous era in FDA’s history, one that will be remembered for the agency’s failure to take aggressive actions at the start of the COVID-19 outbreak,...
BioCentury | Jan 15, 2021
Product Development

Jan. 14 Quick Takes: Pancreatic cancer data lifts NantKwest; plus NIH-Alkermes, Abbott, Inzen

NantKwest Inc. (NASDAQ:NK) rose $3.01 (20%) to $17.79 Thursday after announcing positive interim data from the Phase II QUILT 88 trial in metastatic pancreatic cancer. Early data showed that treatment with PD-L1 t-haNK therapy led...
BioCentury | Jan 15, 2021
Finance

Investors’ picks & access to capital in 2021: a BioCentury podcast

Targeted cancer programs are catching the eyes of buysiders as they kick off the New Year with a positive outlook for the capital markets. On the latest BioCentury This Week podcast, BioCentury editors discuss investor...
BioCentury | Jan 13, 2021
Finance

IPO filing reveals details of Sana’s deep pipeline, aggregation of next-generation gene and cell therapy technologies

With its IPO filing Wednesday, well-funded start-up Sana has lifted the lid on a suite of technologies it has aggregated since 2018, giving it a pipeline of 11 cell and gene therapies. Its first INDs...
BioCentury | Jan 13, 2021
Politics, Policy & Law

BIO, PhRMA ‘pause’ political giving

In the wake of the storming of the U.S. Capitol, BIO and PhRMA have joined other trade associations and U.S. companies in reassessing their criteria for making political contributions. The biopharma trade associations have not...
BioCentury | Jan 11, 2021
Politics, Policy & Law

Trump administration drops defense of ‘most favored nation’ price controls, leaves issue in Biden’s hands

In the face of defeats in three federal courts, the Trump administration has abandoned its attempt to use an administrative shortcut to impose a “most favored nation” international reference pricing scheme on Medicare Part B...
BioCentury | Jan 11, 2021
Politics, Policy & Law

Truth and facts matter. Say it out loud: Editor’s Commentary

First they came for the climate scientists, and I did not speak out because I wasn’t a climate scientist. Then they came for the mask-wearers, and I did not speak out because I was...
BioCentury | Jan 9, 2021
Finance

Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy

After a quiet first nine months, Paris-based VC Jeito ended 2020 with a trio of investments and a €50 million infusion by Sanofi. And while all three venture plays were in early-stage gene and cell...
BioCentury | Jan 8, 2021
Management Tracks

Moderna hires chief commercial officer as it ramps up COVID vaccine rollout; plus MorphoSys, Silence, Verastem, Viking, Destiny and Allen Institute

Corinne Le Goff will join Moderna Inc. (NASDAQ:MRNA) as chief commercial officer on Jan. 19, in the midst of the mRNA company’s launch of its COVID-19 vaccine. Moderna COVID-19 vaccine (mRNA-1273) has emergency use authorization...
Items per page:
1 - 10 of 8237
BioCentury | Jan 21, 2021
Management Tracks

BIO restructures, downsizes as COVID takes toll on in-person events

BIO has restructured its senior management team. It also downsized in response to COVID-19 policies that have forced it to cancel planned in-person conferences and events. The trade association said it expects to hold only...
BioCentury | Jan 20, 2021
Politics, Policy & Law

Exit interview: Hahn departs after tumultuous tenure, advocating greater independence for FDA

FDA Commissioner Stephen Hahn presided over the most tumultuous era in FDA’s history, one that will be remembered for the agency’s failure to take aggressive actions at the start of the COVID-19 outbreak,...
BioCentury | Jan 15, 2021
Product Development

Jan. 14 Quick Takes: Pancreatic cancer data lifts NantKwest; plus NIH-Alkermes, Abbott, Inzen

NantKwest Inc. (NASDAQ:NK) rose $3.01 (20%) to $17.79 Thursday after announcing positive interim data from the Phase II QUILT 88 trial in metastatic pancreatic cancer. Early data showed that treatment with PD-L1 t-haNK therapy led...
BioCentury | Jan 15, 2021
Finance

Investors’ picks & access to capital in 2021: a BioCentury podcast

Targeted cancer programs are catching the eyes of buysiders as they kick off the New Year with a positive outlook for the capital markets. On the latest BioCentury This Week podcast, BioCentury editors discuss investor...
BioCentury | Jan 13, 2021
Finance

IPO filing reveals details of Sana’s deep pipeline, aggregation of next-generation gene and cell therapy technologies

With its IPO filing Wednesday, well-funded start-up Sana has lifted the lid on a suite of technologies it has aggregated since 2018, giving it a pipeline of 11 cell and gene therapies. Its first INDs...
BioCentury | Jan 13, 2021
Politics, Policy & Law

BIO, PhRMA ‘pause’ political giving

In the wake of the storming of the U.S. Capitol, BIO and PhRMA have joined other trade associations and U.S. companies in reassessing their criteria for making political contributions. The biopharma trade associations have not...
BioCentury | Jan 11, 2021
Politics, Policy & Law

Trump administration drops defense of ‘most favored nation’ price controls, leaves issue in Biden’s hands

In the face of defeats in three federal courts, the Trump administration has abandoned its attempt to use an administrative shortcut to impose a “most favored nation” international reference pricing scheme on Medicare Part B...
BioCentury | Jan 11, 2021
Politics, Policy & Law

Truth and facts matter. Say it out loud: Editor’s Commentary

First they came for the climate scientists, and I did not speak out because I wasn’t a climate scientist. Then they came for the mask-wearers, and I did not speak out because I was...
BioCentury | Jan 9, 2021
Finance

Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy

After a quiet first nine months, Paris-based VC Jeito ended 2020 with a trio of investments and a €50 million infusion by Sanofi. And while all three venture plays were in early-stage gene and cell...
BioCentury | Jan 8, 2021
Management Tracks

Moderna hires chief commercial officer as it ramps up COVID vaccine rollout; plus MorphoSys, Silence, Verastem, Viking, Destiny and Allen Institute

Corinne Le Goff will join Moderna Inc. (NASDAQ:MRNA) as chief commercial officer on Jan. 19, in the midst of the mRNA company’s launch of its COVID-19 vaccine. Moderna COVID-19 vaccine (mRNA-1273) has emergency use authorization...
Items per page:
1 - 10 of 8237